JP2020536543A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536543A5 JP2020536543A5 JP2020519704A JP2020519704A JP2020536543A5 JP 2020536543 A5 JP2020536543 A5 JP 2020536543A5 JP 2020519704 A JP2020519704 A JP 2020519704A JP 2020519704 A JP2020519704 A JP 2020519704A JP 2020536543 A5 JP2020536543 A5 JP 2020536543A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- sequence
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091008324 binding proteins Proteins 0.000 claims description 25
- 210000004027 cell Anatomy 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 129
- 229920001184 polypeptide Polymers 0.000 claims 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims 48
- 238000006467 substitution reaction Methods 0.000 claims 32
- 102000014914 Carrier Proteins Human genes 0.000 claims 23
- 239000000427 antigen Substances 0.000 claims 22
- 102000036639 antigens Human genes 0.000 claims 22
- 108091007433 antigens Proteins 0.000 claims 22
- 102000040430 polynucleotide Human genes 0.000 claims 17
- 108091033319 polynucleotide Proteins 0.000 claims 17
- 239000002157 polynucleotide Substances 0.000 claims 17
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 11
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 7
- 102000052645 human CD38 Human genes 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 4
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 3
- 102000018697 Membrane Proteins Human genes 0.000 claims 3
- 108010052285 Membrane Proteins Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 2
- 241000282693 Cercopithecidae Species 0.000 claims 2
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 claims 2
- 101100438926 Macaca fascicularis CD38 gene Proteins 0.000 claims 2
- 102000001708 Protein Isoforms Human genes 0.000 claims 2
- 108010029485 Protein Isoforms Proteins 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 241000282465 Canis Species 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 208000025113 myeloid leukemia Diseases 0.000 claims 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 108091008048 CMVpp65 Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022031377A JP7387780B2 (ja) | 2017-10-10 | 2022-03-02 | 抗ｃｄ３８抗体および使用方法 |
| JP2023193393A JP7733711B2 (ja) | 2017-10-10 | 2023-11-14 | 抗ｃｄ３８抗体および使用方法 |
| JP2025136683A JP2025175288A (ja) | 2017-10-10 | 2025-08-20 | 抗ｃｄ３８抗体および使用方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762570655P | 2017-10-10 | 2017-10-10 | |
| US62/570,655 | 2017-10-10 | ||
| US201762570660P | 2017-10-11 | 2017-10-11 | |
| US62/570,660 | 2017-10-11 | ||
| US201862676221P | 2018-05-24 | 2018-05-24 | |
| US62/676,221 | 2018-05-24 | ||
| EP18187186 | 2018-08-03 | ||
| EP18187186.4 | 2018-08-03 | ||
| PCT/US2018/055084 WO2019074973A2 (en) | 2017-10-10 | 2018-10-09 | ANTI-CD38 ANTIBODIES AND METHODS OF USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022031377A Division JP7387780B2 (ja) | 2017-10-10 | 2022-03-02 | 抗ｃｄ３８抗体および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536543A JP2020536543A (ja) | 2020-12-17 |
| JP2020536543A5 true JP2020536543A5 (https=) | 2021-10-07 |
| JP7036909B2 JP7036909B2 (ja) | 2022-03-15 |
Family
ID=63963620
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020519704A Active JP7036909B2 (ja) | 2017-10-10 | 2018-10-09 | 抗ｃｄ３８抗体および使用方法 |
| JP2022031377A Active JP7387780B2 (ja) | 2017-10-10 | 2022-03-02 | 抗ｃｄ３８抗体および使用方法 |
| JP2023193393A Active JP7733711B2 (ja) | 2017-10-10 | 2023-11-14 | 抗ｃｄ３８抗体および使用方法 |
| JP2025136683A Pending JP2025175288A (ja) | 2017-10-10 | 2025-08-20 | 抗ｃｄ３８抗体および使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022031377A Active JP7387780B2 (ja) | 2017-10-10 | 2022-03-02 | 抗ｃｄ３８抗体および使用方法 |
| JP2023193393A Active JP7733711B2 (ja) | 2017-10-10 | 2023-11-14 | 抗ｃｄ３８抗体および使用方法 |
| JP2025136683A Pending JP2025175288A (ja) | 2017-10-10 | 2025-08-20 | 抗ｃｄ３８抗体および使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11186649B2 (https=) |
| EP (2) | EP4249068A3 (https=) |
| JP (4) | JP7036909B2 (https=) |
| KR (1) | KR20200061402A (https=) |
| CN (4) | CN120058938A (https=) |
| AR (1) | AR116718A1 (https=) |
| AU (1) | AU2018348093A1 (https=) |
| BR (1) | BR112020007002A2 (https=) |
| CA (1) | CA3078800A1 (https=) |
| ES (1) | ES2986579T3 (https=) |
| IL (1) | IL273871A (https=) |
| MA (1) | MA50359A (https=) |
| MX (1) | MX2020004129A (https=) |
| MY (1) | MY199781A (https=) |
| PH (1) | PH12020550408A1 (https=) |
| PY (1) | PY1888702A (https=) |
| SG (1) | SG11202003212PA (https=) |
| TW (4) | TW202430563A (https=) |
| UY (1) | UY37928A (https=) |
| WO (1) | WO2019074973A2 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| TWI743461B (zh) * | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| US12466897B2 (en) | 2011-10-10 | 2025-11-11 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| KR102211837B1 (ko) | 2013-01-14 | 2021-02-03 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| EP3223907A2 (en) | 2014-11-26 | 2017-10-04 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
| PE20171324A1 (es) | 2014-11-26 | 2017-09-11 | Xencor Inc | Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales |
| CN120988137A (zh) * | 2015-01-23 | 2025-11-21 | 赛诺菲 | 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体 |
| RS62437B1 (sr) | 2015-10-25 | 2021-11-30 | Sanofi Sa | Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije |
| CA3020633A1 (en) | 2016-04-13 | 2017-10-19 | Sanofi | Trispecific and/or trivalent binding proteins |
| LT3443006T (lt) | 2016-04-13 | 2023-10-25 | Sanofi | Trispecifiniai ir (arba) trivalenčiai rišantieji baltymai |
| CN109715663B (zh) | 2016-06-28 | 2022-11-25 | Xencor股份有限公司 | 结合生长抑素受体2的异源二聚抗体 |
| IL317134A (en) | 2016-12-21 | 2025-01-01 | Teneobio Inc | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation |
| KR20250007003A (ko) | 2017-06-20 | 2025-01-13 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| BR112020007002A2 (pt) * | 2017-10-10 | 2020-11-17 | Sanofi | anticorpos anti-cd38 e métodos de uso |
| JP2021502100A (ja) | 2017-11-08 | 2021-01-28 | ゼンコア インコーポレイテッド | 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体 |
| CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
| CN112585165B8 (zh) | 2018-04-25 | 2025-02-14 | 普罗米修斯生物科学公司 | 优化的抗tl1a抗体 |
| JP7462621B2 (ja) * | 2018-10-09 | 2024-04-05 | サノフイ | 三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法 |
| WO2020206330A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| EP3953388A1 (en) * | 2019-04-09 | 2022-02-16 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| AU2020299600A1 (en) | 2019-07-03 | 2022-01-06 | Crystal Bioscience Inc. | Anti-CD38 antibody and methods of use thereof |
| AU2020337999A1 (en) * | 2019-08-30 | 2022-03-24 | Dragonfly Therapeutics, Inc. | Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind HER2, NKG2D, and CD16 for cancer treatment |
| NZ787680A (en) | 2019-10-24 | 2026-02-27 | Cedars Sinai Medical Center | Humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof |
| WO2021080649A1 (en) | 2019-10-25 | 2021-04-29 | Sanofi | Methods for analyzing chain mispairing in multispecific binding proteins |
| CN112876563B (zh) * | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技（成都）有限公司 | 药物组合物及其制备方法和应用 |
| IL297601A (en) * | 2020-04-29 | 2022-12-01 | Teneobio Inc | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| TW202330622A (zh) * | 2020-04-29 | 2023-08-01 | 美商泰尼歐生物公司 | 具有經修飾重鏈恆定區之多特異性重鏈抗體 |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| CA3192204A1 (en) * | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| MX2023003214A (es) | 2020-09-18 | 2023-05-24 | Regeneron Pharma | Moleculas de union al antigeno que se unen a cd38 y/o cd28 y usos de las mismas. |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| US11739144B2 (en) | 2021-03-09 | 2023-08-29 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and CLDN6 |
| EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
| WO2023284806A1 (zh) * | 2021-07-14 | 2023-01-19 | 江苏恒瑞医药股份有限公司 | 特异性结合cd38、bcma和cd3的抗原结合分子及其医药用途 |
| US20250277051A1 (en) * | 2021-08-02 | 2025-09-04 | Hangzhou Unogen Biotech, Ltd | Anti-cd38 antibodies, anti-cd3 antibodies, and bispecific antibodies, and uses thereof |
| EP4388000A1 (en) * | 2021-08-20 | 2024-06-26 | Novartis AG | Methods of making chimeric antigen receptor?expressing cells |
| US12365743B2 (en) | 2022-02-23 | 2025-07-22 | Xencor, Inc. | Anti-CD28 x anti-PSMA antibodies |
| EP4540284A2 (en) | 2022-06-17 | 2025-04-23 | Apogee Therapeutics, Inc. | Antibodies that bind interleukin 13 and methods of use |
| CN119487071A (zh) * | 2022-06-24 | 2025-02-18 | 北京可瑞生物科技有限公司 | 基于t细胞受体的双特异性多肽分子及其用途 |
| WO2024206439A2 (en) * | 2023-03-28 | 2024-10-03 | Nkarta, Inc. | Antibodies and chimeric antigen receptors specific for cd38 |
| WO2025027003A1 (en) | 2023-07-31 | 2025-02-06 | Sanofi | Methods and uses for anti-cd38 t cell engagers in treatment of peripheral t-cell lymphomas |
| WO2025209594A1 (zh) * | 2024-04-06 | 2025-10-09 | 华深智药生物科技(苏州)有限公司 | 一种抗gucy2c抗体及其多特异性抗体的用途 |
| TW202602939A (zh) * | 2024-04-06 | 2026-01-16 | 大陸商華深智藥生物科技（蘇州）有限公司 | 一種多特異性抗體t細胞銜接器 |
| WO2026019667A1 (en) * | 2024-07-17 | 2026-01-22 | Jn Biosciences Llc | Trispecific antibodies for activation of immune cells |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3850542T2 (de) | 1987-09-23 | 1994-11-24 | Bristol Myers Squibb Co | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
| CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
| WO2004106375A1 (en) * | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
| NZ544924A (en) * | 2003-06-27 | 2009-03-31 | Biogen Idec Inc | Modified binding molecules comprising connecting peptides |
| US9200061B2 (en) * | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| KR20140066259A (ko) * | 2004-02-06 | 2014-05-30 | 모르포시스 아게 | 항-ｃｄ３８ 인간 항체 및 그의 용도 |
| CN100376599C (zh) | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
| JP5225069B2 (ja) * | 2005-03-23 | 2013-07-03 | ゲンマブ エー／エス | 多発性骨髄腫の治療のためのｃｄ３８に対する抗体 |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| CA2726087A1 (en) | 2008-06-03 | 2009-12-10 | Tariq Ghayur | Dual variable domain immunoglobulins and uses thereof |
| CA2774636C (en) | 2009-09-25 | 2019-05-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to hiv-1 and their use |
| SMT202000031T1 (it) | 2010-06-09 | 2020-03-13 | Genmab As | Anticorpi contro cd38 umano |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| TWI743461B (zh) | 2011-03-28 | 2021-10-21 | 法商賽諾菲公司 | 具有交叉結合區定向之雙重可變區類抗體結合蛋白 |
| WO2012154312A1 (en) | 2011-05-09 | 2012-11-15 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralizing antibodies to hiv-1 and their use |
| CN103797029B (zh) | 2011-05-17 | 2016-08-17 | 洛克菲勒大学 | 人类免疫缺陷病毒中和抗体及其使用方法 |
| BR112014010823B1 (pt) | 2011-11-07 | 2021-02-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | anticorpos que se ligam a gp41 e neutralizam o vírus da imunodeficiência humana tipo 1 (hiv-1), seus usos, molécula de ácido nucleico, vetor de expressão, composição, kit, bem como métodos de detecção de infecção pelo hiv-1 e de teste de imunógeno potencial |
| EP2788376B1 (en) | 2011-12-08 | 2018-10-03 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Neutralizing antibodies to hiv-1 and their use |
| HUE033245T2 (hu) * | 2011-12-19 | 2017-11-28 | Synimmune Gmbh | Bispecifikus ellenanyag molekula |
| WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
| WO2014089152A1 (en) | 2012-12-04 | 2014-06-12 | University Of Maryland, Baltimore | Hiv-1 env-binding antibodies, fusion proteins, and methods of use |
| US20140213772A1 (en) | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Cross-over dual variable domain immunoglobulin constructs |
| US10487155B2 (en) * | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| WO2014116846A2 (en) | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
| CN105209491A (zh) | 2013-03-15 | 2015-12-30 | 艾伯维公司 | 针对TNFα的双重特异性结合蛋白 |
| JP2016538275A (ja) * | 2013-11-04 | 2016-12-08 | グレンマーク ファーマシューティカルズ， エセ．アー． | Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造 |
| EP3699195A3 (en) | 2014-03-28 | 2020-11-04 | Xencor, Inc. | Bispecific antibodies that bind to cd38 and cd3 |
| CN106687584B (zh) | 2014-09-04 | 2021-08-13 | 干细胞技术公司 | 用于t细胞或nk细胞活化和扩增的可溶性抗体复合物 |
| JP6180663B2 (ja) * | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| CN120988137A (zh) | 2015-01-23 | 2025-11-21 | 赛诺菲 | 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体 |
| WO2016196740A1 (en) | 2015-06-02 | 2016-12-08 | The Rockefeller University | Tri-specific antibodies for hiv therapy |
| RS62437B1 (sr) | 2015-10-25 | 2021-11-30 | Sanofi Sa | Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije |
| CN105837688B (zh) * | 2015-11-20 | 2019-02-26 | 北京大学深圳研究生院 | 单域抗体及其编码基因，免疫毒素及其编码基因、制备方法、表达载体、应用，及宿主细胞 |
| CA3020633A1 (en) | 2016-04-13 | 2017-10-19 | Sanofi | Trispecific and/or trivalent binding proteins |
| WO2018120842A1 (zh) | 2016-12-30 | 2018-07-05 | 上海欣百诺生物科技有限公司 | 一种双功能分子及其应用 |
| WO2018151841A1 (en) | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
| BR112020007002A2 (pt) | 2017-10-10 | 2020-11-17 | Sanofi | anticorpos anti-cd38 e métodos de uso |
| JP7462621B2 (ja) | 2018-10-09 | 2024-04-05 | サノフイ | 三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法 |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
-
2018
- 2018-10-09 BR BR112020007002-5A patent/BR112020007002A2/pt not_active IP Right Cessation
- 2018-10-09 MA MA050359A patent/MA50359A/fr unknown
- 2018-10-09 US US16/155,807 patent/US11186649B2/en active Active
- 2018-10-09 AU AU2018348093A patent/AU2018348093A1/en not_active Abandoned
- 2018-10-09 CN CN202510116993.7A patent/CN120058938A/zh active Pending
- 2018-10-09 ES ES18792827T patent/ES2986579T3/es active Active
- 2018-10-09 SG SG11202003212PA patent/SG11202003212PA/en unknown
- 2018-10-09 MX MX2020004129A patent/MX2020004129A/es unknown
- 2018-10-09 CN CN202311405579.5A patent/CN117964758A/zh active Pending
- 2018-10-09 EP EP23173927.7A patent/EP4249068A3/en active Pending
- 2018-10-09 CA CA3078800A patent/CA3078800A1/en active Pending
- 2018-10-09 KR KR1020207013073A patent/KR20200061402A/ko active Pending
- 2018-10-09 MY MYPI2020001741A patent/MY199781A/en unknown
- 2018-10-09 CN CN201880079045.9A patent/CN111788225B/zh active Active
- 2018-10-09 WO PCT/US2018/055084 patent/WO2019074973A2/en not_active Ceased
- 2018-10-09 CN CN202510123093.5A patent/CN120058939A/zh active Pending
- 2018-10-09 EP EP18792827.0A patent/EP3694882B1/en active Active
- 2018-10-09 JP JP2020519704A patent/JP7036909B2/ja active Active
- 2018-10-10 UY UY0001037928A patent/UY37928A/es not_active Application Discontinuation
- 2018-10-10 PY PY201801888702A patent/PY1888702A/es unknown
- 2018-10-11 TW TW112139669A patent/TW202430563A/zh unknown
- 2018-10-11 TW TW107135898A patent/TWI821202B/zh not_active IP Right Cessation
- 2018-10-11 TW TW112124284A patent/TW202342544A/zh unknown
- 2018-10-11 TW TW112139671A patent/TW202432580A/zh unknown
-
2019
- 2019-10-08 AR ARP190102858A patent/AR116718A1/es unknown
-
2020
- 2020-04-07 IL IL273871A patent/IL273871A/en unknown
- 2020-04-10 PH PH12020550408A patent/PH12020550408A1/en unknown
-
2021
- 2021-10-15 US US17/503,038 patent/US11365261B2/en active Active
-
2022
- 2022-03-02 JP JP2022031377A patent/JP7387780B2/ja active Active
- 2022-05-05 US US17/737,814 patent/US20220275102A1/en active Pending
-
2023
- 2023-11-14 JP JP2023193393A patent/JP7733711B2/ja active Active
-
2025
- 2025-08-20 JP JP2025136683A patent/JP2025175288A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536543A5 (https=) | ||
| JP7662516B2 (ja) | Ｐｄ－１標的化ｉｌ－１５／ｉｌ－１５ｒアルファｆｃ融合タンパク質およびその組み合わせ療法での使用 | |
| CN110914306B (zh) | 检查点抑制物双特异性抗体 | |
| TWI788286B (zh) | 三特異性和/或三價結合蛋白 | |
| JP6702893B2 (ja) | 多重特異的抗原結合タンパク質 | |
| US20240010748A1 (en) | Bispecific antibody for claudin 18a2 and cd3 and application of bispecific antibody | |
| JP2021098732A (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｅｇｆｒ、ｃｃｒ４、またはｐｄ−ｌ１に結合するタンパク質 | |
| JP2018531219A (ja) | Ｐｄ−ｌ１抗体 | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| CN104903352A (zh) | 多价结合蛋白组合物 | |
| JP2023538945A5 (https=) | ||
| CN116396386A (zh) | Cd3抗体及其药物用途 | |
| JP2022552183A (ja) | 特性が改善されたｐｄ－１標的化ｉｌ－１５／ｉｌ－１５ｒαｆｃ融合タンパク質 | |
| TW201333035A (zh) | 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白 | |
| WO2021185337A1 (zh) | 一种双特异性融合蛋白及其应用 | |
| TW201333033A (zh) | 雙可變域免疫球蛋白及其用途 | |
| JP2022551836A (ja) | Ｂｃｍａを標的とする抗体、二重特異性抗体及びその用途 | |
| US20240002544A1 (en) | Cd28 bispecific antibodies for targeted t cell activation | |
| US20230365709A1 (en) | Trispecific binders | |
| JP7080219B2 (ja) | 共刺激受容体およびチェックポイント受容体に連結する二重特異性免疫調節抗体 | |
| JP2024530451A (ja) | 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体及び応用 | |
| JP2019529368A5 (https=) | ||
| JP7418326B2 (ja) | 二重特異性抗体並びにその製造方法及び使用方法 | |
| US20250188166A1 (en) | Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof | |
| JP2019537449A5 (https=) |